6.86
+0.21
(3.16%)
May 24 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 6.56 - 6.90 |
| 52 week | 4.30 - 16.68 |
| Open | 6.64 |
| Vol / Avg. | 899,990.00/800,994.00 |
| Mkt cap | 212.56M |
| P/E | - |
| Div/yield | - |
| EPS | -2.09 |
| Shares | 30.99M |
| Beta | - |
| Inst. own | 89% |
Events
Jun 4, 2013
Supernus Pharmaceuticals at Jefferies Global Healthcare Conference
- 10:00AM EDT -
May 30, 2013
Supernus Pharmaceuticals at Deutsche Bank dbAccess Health Care Conference
- 2:50PM EDT -
May 13, 2013
Q1 2013 Supernus Pharmaceuticals Earnings Conference Call
Mar 14, 2013
Q4 2012 Supernus Pharmaceuticals Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -12526.53% | -3127.30% |
| Operating margin | -12182.31% | -2849.26% |
| EBITD margin | - | -2774.93% |
| Return on average assets | -85.36% | - |
| Return on average equity | -149.45% | - |
| Employees | 193 | - |
| Carbon Disclosure Rating | - | - |
Address
1550 East Gude Drive
ROCKVILLE, MD 20850
United States - Map
+1-301-8382500 (Phone)
+1-302-6555049 (Fax)
ROCKVILLE, MD 20850
United States - Map
+1-301-8382500 (Phone)
+1-302-6555049 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Volume delayed by 15 mins.
Advertisement
Description
Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.
Officers and directors
| M. James Barrett Ph.D. | Independent Chairman of the Board | |
| Jack A. Khattar | President, Chief Executive Officer, Director | |
| Gregory S. Patrick | Chief Financial Officer, Vice President | |
| Stefan K.F. Schwabe M.D., Ph.D. | Executive Vice-President - Research & Development, Chief Medical Officer | |
| Padmanabh P. Bhatt Ph.D. | Senior Vice President- Intellectual Property, Chief Scientific Officer | |
| Victor Vaughn | Senior Vice President - Sales | |
| Tami T. Martin Esq. | Vice President - Regulatory Affairs | |
| Jones W. Bryan Ph.D. | Vice President - Business Development | |
| Michael F. Bigham | Independent Director | |
| Frederick M. Hudson | Independent Director |